EQL PHARMA AB Total Assets
EQL PHARMA AB total assets. Based on the latest financial reports, EQL PHARMA AB (7JK) holds total assets worth €850.89 Million EUR (≈ $994.78 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 7JK company net worth for the company's overall valuation and market capitalisation.
Total Assets of EQL PHARMA AB (2022–2026)
Total assets of EQL PHARMA AB from 2022 to 2026. This chart illustrates how EQL PHARMA AB's total assets have evolved over time, based on quarterly financial data. See latest EQL PHARMA AB stock price today for real-time trading data and today's change.
EQL PHARMA AB - Asset Composition Analysis
EQL PHARMA AB Total Assets Breakdown (March 2026)
EQL PHARMA AB total assets breakdown as of March 2026. EQL PHARMA AB's total assets of €850.89 Million consist of 47.5% current assets and 52.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 10.2% |
| Accounts Receivable | €92.74 Million | 10.9% |
| Inventory | €200.53 Million | 23.6% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €441.11 Million | 51.8% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2022–2026)
This chart illustrates how EQL PHARMA AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore EQL PHARMA AB short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: EQL PHARMA AB's current assets represent 47.5% of total assets in 2026, a decrease from 51.9% in 2022.
- Cash Position: Cash and equivalents constituted 10.2% of total assets in 2026, down from 17.3% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 51.0% of total assets, an increase from 46.0% in 2022.
- Asset Diversification: The largest asset category is intangible assets at 51.8% of total assets.
EQL PHARMA AB Competitors by Total Assets
Key competitors of EQL PHARMA AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329
|
China | CN¥11.59 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
EQL PHARMA AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.92 | 1.81 | 1.24 |
| Quick Ratio | 0.97 | 1.00 | 0.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €193.64 Million | €179.23 Million | €45.79 Million |
EQL PHARMA AB - Advanced Valuation Insights
This section examines the relationship between EQL PHARMA AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.35 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | 5.2% |
| Total Assets | €850.89 Million |
| Market Capitalization | $59.21 Million USD |
Valuation Analysis
Below Book Valuation: The market values EQL PHARMA AB's assets below their book value (0.07x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: EQL PHARMA AB's assets grew by 5.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for EQL PHARMA AB (2022–2026)
The table below shows the annual total assets of EQL PHARMA AB from 2022 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-03-31 | €850.89 Million ≈ $994.78 Million |
+5.20% |
| 2025-03-31 | €808.82 Million ≈ $945.60 Million |
+116.40% |
| 2024-03-31 | €373.76 Million ≈ $436.96 Million |
+30.82% |
| 2023-03-31 | €285.70 Million ≈ $334.01 Million |
+20.10% |
| 2022-03-31 | €237.89 Million ≈ $278.12 Million |
-- |
About EQL PHARMA AB
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers prescription drugs, including hospital products. EQL Pharma AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.